



CATEGORY: BEST PRACTICE STATEMENT

Prophylactic antibiotics in obstetrics and gynaecology

This statement has been developed and reviewed by the Women's Health Committee and approved by the RANZCOG Board and Council.

A list of Women's Health Committee Members can be found in [Appendix A](#).

Disclosure statements have been received from all members of this committee.

This information is intended to provide general advice to practitioners. This information should not be relied on as a

Objectives: To provide advice on the use of prophylactic antibiotics in obstetrics and gynaecology.

Target audience: Health professionals providing maternity and gynaecological care, and patients.

Values: The evidence was reviewed by the Women's Health Committee (RANZCOG), and applied to local factors relating to Australia and New Zealand.

Background: This statement was first developed by Women's Health Committee in November 2011 and reviewed in March 2021.

Funding: The development and review of this statement was funded by RANZCOG.

Table of contents

| | |
|--|----|
| 1. Plain language summary | 3 |
| 2. Summary of recommendations | 3 |
| 3. Introduction | 3 |
| 4. Discussion and recommendations | 3 |
| 4.1 Caesarean section | 3 |
| 4.2 Operative vaginal delivery | 4 |
| 4.3 Group B streptococcus | 5 |
| 4.4 Preterm prelabour rupture of membranes (PPROM) to 36 + 6 weeks gestation | 5 |
| 4.5 Prophylactic antibiotics in obstetrics | 5 |
| 4.6 Prophylactic antibiotics in gynaecology | 5 |
| 5. References | 7 |
| 6. Other suggested reading | 7 |
| 7. Links to other College statements | 7 |
| Appendices | 8 |
| Appendix A Women’s Health Committee Membership | 8 |
| Appendix B Overview of the development and review process for this statement | 8 |
| Appendix C Full Disclaimer | 11 |

Plain language summary

Operative vaginal delivery

Operative delivery, much like caesarean section, is a risk factor for maternal sepsis. Historically insufficient evidence existed to recommend antibiotics prophylaxis for women undergoing operative vaginal birth. This changed in 2019 with the publication of the ANODE trial. The ANODE trial demonstrated that prophylaxis with a single dose of intravenous amoxicillin and clavulanic acid resulted in significantly fewer confirmed or suspected infections when compared to placebo. The dose given was 1g amoxycillin and 200mg clavulanic acid once intravenously².

Group B streptococcus

All women with known carriage or risk factors for Group B str

-

The choice of prophylactic antibiotics in PPROM will also depend on whether clinical signs of

Links to other College statements

Screening and Treatment for Group B Streptococcus in Pregnancy (C-Obs 19)

[https://ranzcof.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical-Obstetrics/Maternal-Group-B-Streptococcus-in-pregnancy-screening-and-management-\(C-Obs-19\).pdf?ext=.pdf](https://ranzcof.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical-Obstetrics/Maternal-Group-B-Streptococcus-in-pregnancy-screening-and-management-(C-Obs-19).pdf?ext=.pdf)

Prophylactic

Appendix C Full Disclaimer

Purpose

This Guideline has been developed to provide general advice to practitioners about women's